MAM
M&C Saatchi India appoints Suranjan Das as executive director
MUMBAI: M&C Saatchi India, the Indian arm of the UK-based global advertising agency, has appointment Suranjan Das as executive director. In his new role, Das will be heading the agency‘s Mumbai office.
Prior to this, Das was VP and client services director at JWT Mumbai, before he was seconded to head Fortune Communications, a wholly owned subsidiary of JWT India in January 2006. |
Said M&C Saatchi India chairman and MD Kamal Oberoi, “Suranjan inherits an operation that is fast developing a reputation for creative excellence. I am certain Suranjan will ensure that our creative excellence continues and that our office will make great strides in developing and attracting new business.” |
At JWT, Das handled various categories of businesses that included FMCG, consumer products (HLL- Lux, Sunsilk, Pears; GSL – Good Knight, Emami, Chateau Indage Vineyards), durables (Philips, VIP Luggage, Godrej Appliances), finance (Citibank, StanChart Bank, Stanchart AMC, LIC), travel & hospitality (Air India, ITC Welcomgroup- Sea Rock); and beverages (Smirnoff). |
MAM
Beacon Group appoints Dr Rajesh Patel as Group CEO
36-year healthcare veteran to lead Beacon Diagnostics, Vector Biotek, Biogeny.
MUMBAI: A new chief, a fresh diagnosis and a sharper prescription for growth. Beacon Group has appointed Dr Rajesh Patel as its Group Chief Executive Officer, effective April 1, 2026, signalling a decisive push to scale its presence in the diagnostics and IVD space. Patel steps into the role with 36 years of experience across the healthcare and diagnostics industry, bringing a career shaped by leadership roles spanning sales, marketing, business development and operational strategy. His mandate is both expansive and precise: to steer the group’s overall strategic direction while tightening coordination across its three core entities Beacon Diagnostics, Vector Biotek and Biogeny Diagnostics.
In practical terms, that means driving cross-company synergies, accelerating market expansion and strengthening organisational capability areas increasingly critical as diagnostic players compete for scale in a fragmented yet rapidly evolving healthcare ecosystem. The group is positioning itself to capture unmet demand across chain laboratories, key accounts and standalone labs, segments that remain underserved despite growing diagnostic needs.
The appointment comes at a time when the In Vitro Diagnostics (IVD) sector in India is entering a more competitive and innovation-led phase, with companies focusing not just on product pipelines but also on service delivery, integration and customer-centric models. Beacon’s leadership appears to be betting that Patel’s execution-focused approach can help translate ambition into operational momentum.
Welcoming the appointment, Chairman Dr D K Joshi described Patel’s induction as a strategic move aligned with the group’s long-term vision, emphasising the role of leadership depth in navigating the next phase of growth.
For Beacon Group, the message is clear, in a sector where precision matters, leadership is the new differentiator—and this appointment is intended to set the tone for what comes next.
